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Abstract 
GTP and ATP are necessary for glucose-induced insulin secretion; however, the biosynthetic pathways of purine nucleotides have not 
been studied in pancreatic islets. The present work examines the cytosolic pathways of purine nucleotide synthesis using intact rat islets 
cultured overnight in RPMI 1640 medium containing either [14C]glycine (to label the de novo pathway) or [3H]hypoxanthine (tomark the 
salvage pathway), with or without mycophenolic acid or L-alanosine (selective inhibitors of cytosolic GTP and ATP synthesis, 
respectively). Addition of mycophenolic acid decreased total GTP content (mass) by 73-81%; although the incorporation of labeled 
hypoxanthine into GTP also fell by 87%, the incorporation of glycine did not change. Similarly, L-alanosine decreased ATP mass by 
26-33% in the presence of either label; whereas the incorporation of hypoxanthine into ATP fell 59%, the incorporation of glycine was 
again not significantly decreased. Thus, both the de novo and salvage purine nucleotide biosynthetic pathways are present in rat islets; 
however, the salvage pathway appears to be quantitatively the more important source of nucleotides. This conclusion was supported by 
additional studies of the effects on nucleotide content and insulin secretion of various site-specific inhibitors of purine synthesis. These 
findings have potential relevance to the processes of mitogenesis, cell proliferation and differentiation of islet cells, as well as for the 
control of insulin secretion. 
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1. Introduction 
There is considerable interest in the roles of the purine 
nucleotides GTP and ATP in the function of the pancreatic 
islet. ATP is widely accepted to facilitate exocytotic in- 
sulin release, although its exact effect(s) remains contro- 
versial [1]. The role of GTP has received less investigation; 
however, our recent studies in islets [2] and those of 
Gomperts et al. using mast cells [3] suggest a mediator 
and/or  permissive role for GTP in exocytosis. 
There are only scanty extant data regarding the path- 
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ways leading to the synthesis of purine nucleotides in 
pancreatic islets or other endocrine glands. Non-endocrine 
cells contain two major purine biosynthetic pathways (the 
de novo and 'salvage' pathways; Fig. 1), which make 
variable contributions to total nucleotide mass, depending 
on cell type. Both are located entirely in the cytosol [4] and 
produce adenine and guanine monophosphates, from which 
ATP and GTP are ultimately synthesized through phospho- 
rylation reactions in the cytosol and/or  mitochondria. Our 
preliminary data have shown that both pathways are pre- 
sent in islets and that they are both stimulated by glucose 
[5]. However, an analysis of the relative importance of 
individual pathways in islets (or other endocrine tissues) is 
lacking. Additionally, data from non-endocrine tissues sug- 
gest that purine nucleotides may be compartmentalized 
within the cell [1,6,7]. In the islet, this might also be of 
considerable significance. For example, the role proposed 
for ATP to initiate glucose-induced insulin release by 
closing a plasma membrane K ÷ channel (reviewed in [1]) 
would seem to dictate a biosynthetic locus at or near this 
ion channel (i.e., a cytosolic source of ATP); alternatively, 
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Fig. 1. Biosynthetic pathways of adenine and guanine nucleotides. Dashed 
lines indicate that more than one step is involved. The dinucleotides ADP 
and GDP are formed as intermediates in the conversion of NMP ~ NTP, 
and the enzymes that catalyze these reactions are not included in this 
figure, a, amidophosphoribosy]transferase and phosphoribosylformyl- 
glycinamide synthetase; b, phosphoribosylglycinamide synthetase; c, 
adenylosuccinate synthetase; d, IMPDH; e, HGPRTase; f, STK or NDPK; 
g, NDPK or ATP synthase. Steps a, b, c, d, and e are found in the 
cytusol. STK and ATP synthase are present in the mitochondria. NDPK is 
primarily found in the cytosol, but may be present in mitochondria s 
well. 
ATP might be 'channeled' from the mitochondria to the 
plasma membrane, where it could accumulate to high 
concentrations. 
Therefore, in the current study we have attempted to 
define for the first time the biosynthetic sources of adenine 
and guanine nucleotides in normal, intact rat pancreatic 
islets, using radiolabels specific to the de novo 
([tac]glycine) and the salvage ([3H]hypoxanthine) path- 
ways, in conjunction with selective inhibitors of cytosolic 
purine nucleotide biosynthesis. Islet purine nucleotide con- 
tent was analyzed in terms both of total mass and radioac- 
tivity derived from the synthetic precursors, in order to 
quantify changes in the specific activities of different 
nucleotide pools and to estimate the relative importance of 
the different pathways. 
2. Methods  
2.1. Materials 
Test compounds were purchased from Sigma (St. Louis, 
MO) except for L-alanosine (provided courtesy of the Drug 
Synthesis and Chemistry Branch, National Cancer Insti- 
tute). [3H(G)]hypoxanthine (17 Ci/mmol) and [t4C(U)] 
glycine (110.5 mCi/mmol) were purchased from New 
England Nuclear (Boston, MA) or Amersham (Arlington 
Heights, IL). RPMI 1640 medium was purchased from 
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Fig. 2. Example of HPLC nucleotide chromatogram asquantified by UV spectroscopy at254 nM (main panels) or by incorporation of [3H]hypoxanthine 
into ATP and GTP (inset). Panel A, typical chromatogram from the extract of approx. 35 control islets cultured at 11.1 mM glucose. Panel B, typical 
chromatogram from the extract of approx. 35 islets cultured at 11.1 mM glucose in the presence of 300/xM 6-mercaptopurine, illustrating the decrease in 
GTP and ATP, with the two internal standards (CTP and ITP) flanking these nucleotides. Inset, incorporation of [3H]hypoxanthine into GTP and ATP 
quantified in the eluant from the corresponding chromatograms in Panels A and B. A254, absorbance at254 nm. 
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Gibco (Grand Island, NY). L-Glutamine (Gln, 2.05 mM) 
was present in the culture medium to provide adequate 
substrate for the de novo synthesis of purine nucleotides 
[8], except where noted otherwise; where indicated, Gin or 
glycine content was selectively modified using the Select- 
Amine kit from Gibco. 
2.2. Determination of nucleotide content of islets 
Intact pancreatic islets were isolated from adult male 
Sprague-Dawley rats as previously described, followed by 
double hand-picking under stereomicroscopic control in 
order to eliminate any contaminating acinar tissue [9]. 200 
islets for each condition were cultured overnight (× 18 h) 
in RPMI 1640 medium with 11.1 mM glucose and 10% 
fetal bovine serum. 11.1 mM glucose was chosen because 
our previous data demonstrated that the effect of MPA on 
glucose-induced insulin secretion was maximal at this 
glucose concentration [2]. 11.1 mM glucose was also 
found to stimulate both the de novo and salvage pathways 
of nucleotide synthesis to a comparable extent; such stimu- 
lation would maximize the chance that effects of the 
inhibitors of the two pathways could be easily quantified, 
if present. 
Nucleotides were extracted using 0.6 N TCA, followed 
by removal of TCA using diethyl ether as described in 
detail in [2]. Nucleotides were separated and measured by 
anion-exchange HPLC as previously described [2]. In brief, 
buffer A was 0.5 mM NHaH2PO4, pH 2.5-2.65; buffer B 
was 0.65 M NH4H2PO4, pH 2.5-2.65. Nucleotides were 
separated isocratically; the concentrations of buffers A and 
B varied between studies, as did the pH, in order to 
maximize separation of compounds. Absorbance was mon- 
itored at 254 nm. 50-100 /~1 of extract was injected in 
duplicate. ITP and CTP were added to extracts as internal 
standards, since previous studies had shown that these 
nucleotides were not detectable ndogenously in islet ex- 
tracts. Nucleotide concentrations were calculated from a 
standard curve run daily and corrected for recovery of ITP 
and CTP. Values for recoveries of internal standards (ITP, 
CTP) have been previously reported, as have been the 
coefficients of variation for the overall precision of the 
measurements [2]. A representative chromatogram is shown 
in Fig. 2. 
2.3. Labeling of purine nucleotides via the de novo or 
salvage pathways 
Islets were treated exactly as described above except for 
the addition of 10 /zCi/ml of [14C(U)]glycine (which 
donates carbons at position 4 and 5, and nitrogen at 
position 7, of the purine ring, ref. [4]), or with 2 /xCi/ml 
of [3H(G)]hypoxanthine (a substrate for hypoxanthine- 
guanine phosphoribosyltransferase, ref. [4]) over an identi- 
cal 18 h period (see Fig. 1). The mass of exogenous 
labeled hypoxanthine was kept low (~ 120 nM), and 
labeled glycine replaced an equal mass of unlabeled glycine 
in the RPMI 1640 media, so as not to alter the basic 
conditions used in our previous studies [2,5]. Islets were 
extracted as described above following an additional rapid 
wash in 1 ml Krebs-Ringer Bicarbonate buffer containing 
0.5% BSA at room temperature to remove any unincorpo- 
rated radiolabeled compounds adherent to the islets. Eluant 
HPLC fractions were collected every 30 s (glycine label) 
or every 18 s (hypoxanthine label) and were matched 
against he concomitant UV chromatograms (Fig. 2, inset). 
2.4. Treatment of pancreatic islets for studies of insulin 
release 
The incubation medium for insulin release studies (car- 
ried out after overnight culture) was Krebs-Ringer Bicar- 
bonate buffer (pH 7.4) containing 0.5% BSA and 3.3 mM 
glucose (for basal release) or 16.7 mM glucose (for stimu- 
lated release), and gassed with 95% 02/5% CO 2. Static, 
batch-type incubations were carried out for 40-45 min as 
indicated. Inhibitory drugs (e.g. MPA, alanosine) were 
present during not only the 18 h culture period but also 
were included in islet picking, wash, and preincubation 
steps the following day, in order to avoid attenuation of 
their effects over time. However, drugs were excluded 
from the incubation period, to avoid any possible non- 
specific drug effects or interference with the insulin RIA. 
In addition, it was first verified that an acute exposure (up 
to 90 min) to MPA, alanosine, or 6-mercaptopurine had no 
effect on glucose-induced insulin secretion (data not 
shown). Insulin content of media was measured by RIA 
after extraction, as described [10]. 
2.5. Data presentation and statistical analysis 
Data are expressed as mean _ S.E., with n representing 
the number of observations in a representative study, or the 
number of separate xperiments, as indicated. Insulin se- 
cretion is expressed as absolute incremental release calcu- 
lated as the value for insulin released under stimulated 
conditions minus the mean value for basal release (i.e., at 
3.3 mM glucose) in that same study. Some fractional 
release rates are also presented to take into account any 
effects on absolute rates of secretion caused by alterations 
in insulin content induced by the various pharmacological 
inhibitors. Fractional release was calculated by the for- 
mula: 
( insulin released ) 
initial insulin content 
where the denominator equals the insulin content re- 
maining in islets at the end of the incubation period plus 
the insulin released during the incubation period. Frac- 
tional release is expressed as the percent of initial insulin 
content which was released over 45 min. Statistical analy- 
ses were by ANOVA and/or non-paired t-tests, as appro- 
priate. 
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Table 1 
Effects of MPA or of L-alanosine on the incorporation of [3H]hypoxanthine or [14C]glycine into GTP and ATP, and on total islet content of GTP and ATP 
Treatment Radioactivity (DPM/islet) Mass (pmol/islet) Specific Activity (DPM/pmol) 
A. [3H]Hypoxanthine label 
1. GTP 
2. ATP 
B. [14C]Glycine label 
1. GTP 
2. ATP 
Control (n = 10) 388___ 71 3.76 + 0.13 104+ 5 
Alanosine (n = 7) 404+ 30 4.19 + 0.31 97+ 1 
MPA(n = 8) 50+ 9 b 0.70 + 0.02 b 69+ 12 b 
Control (n = 10) 2013 + 81 13.41 _ 0.48 152-+- 8
Alanosine (n = 7) 840+ 67 b 9.36 _ 0.57 b 91 ___ 6 b 
MPA (n = 8) 973 + 36 b 7.55 + 0.17 b 129_+ 4 a 
Control (n = 5) 4.54 _+ 0.84 3.25 + 0.25 1.42 + 0.24 
Alanosine (n = 6) 8.02 5= 0.69 a 3.92 + 0.17 b 2.05 _+ 0.17 
MPA (n = 6) 4.85 + 0.66 0.89 + 0.06 b 5.36 + 0.47 b 
Control (n = 6) 18.69 + 0.82 11.93 -I- 1.40 1.66 + 0.20 
Alanosine (n = 6) 15.54 + 1.35 8.81 + 0.41 a 1.76 + 0.11 
MPA (n = 6) 42.15 _ 1.44 b 8.30 + 0.72 a 5.22 + 0.33 b 
Islets were cultured 18 h in RPMI media at 11.1 mM glucose with either 10 ~Ci/ml [14C]glycine or2 ~Ci/ml [3H]hypoxanthine  the presence of MPA 
(25 /xg/ml) or alanosine (300-600 /xM) as indicated. 
n = number of determinations (mean + S.E.). 
a p < 0.05 vs. control (diluent alone). 
b p < 0.001 vs. control (diluent alone). 
3. Results 
Either labeled glycine or labeled hypoxanthine was 
incorporated into both GTP and ATP in rat islets (Table 
1); therefore, both the de novo and salvage pathways of 
purine nucleotide biosynthesis are present in rat pancreatic 
islets. In order to estimate the relative importance of each 
pathway, site-selective inhibitors of purine synthesis were 
employed as described below. 
3.1. GTP Synthesis 
Mycophenol ic acid (MPA) was chosen to study guanine 
nucleotide biosynthesis because it is a selective inhibitor of 
inosine monophosphate dehydrogenase ( IMPDH; [11]), 
which catalyzes the rate-l imiting step in the formation of 
guanine nucleotides from inosine monophosphate (IMP). 
Treatment of islets with MPA in our previous studies [2,5] 
resulted in an 80% decrease in total cellular GTP content. 
In the current studies, MPA similarly reduced total islet 
GTP content (mass) in islets labeled with [3H]hypo- 
xanthine ( -81%)  or with [14C]glycine ( -73%;  Table 1). 
MPA also reduced incorporation of [3H]hypoxanthine into 
GTP by 87% (Table 1). The decline in counts was greater 
than the decline in mass, and therefore the specific activity 
also fell by 33%. Since an 87% inhibition of IMPDH by 
MPA (by counts) lowered GTP content by 81%, one can 
estimate (by their product) that as much as 90% of cellular 
GTP may ultimately be derived from pool(s) of IMP 
dependent on salvage. 1 Contrasting results were obtained 
in islets labeled with [14C]glycine (to label the de novo 
pathway). Although GTP content dropped 73%, MPA did 
not significantly affect the incorporation of labeled glycine 
into GTP (Table 1); therefore, the specific activity of 
labeled GTP actually increased. 
Islets were next cultured with succinic acid monomethyl  
ester (SAME), which is hydrolyzed intracellularly to suc- 
cinic acid. Prolonged increases in succinic acid, as a 
substrate for succinate thiokinase in the mitochondria, 
would consume (and thereby should deplete) mitochon- 
drial GTP, in the reaction yielding succinyl CoA [13]. 
Since GTP is not a substrate for the adenine nucleotide 
translocase and thus is not known to cross the inner 
mitochondrial membrane [14], any decrement should repre- 
sent the GTP compartmental ized to the mitochondria. To- 
tal islet GTP content decreased only 8 -12% (P  = 0.11, 14 
df) in islets cultured in the presence of 2.5 or 4.0 mM 
SAME (data not shown). This figure is probably a modest 
underestimate, since SAME also tended to reduce ATP 
content, by an average of 1.20 pmol / i s le t  (control = 16.36 
+ 1.14 pmol / i s le t  control; SAME = 15.16 ___ 1.15 
pmol / is let ;  n = 7; P = 0.52), representing consumption of 
ATP used to regenerate GTP via guanylate kinase and/or  
nucleoside diphosphokinase [7,15] 2. 
3.2. ATP Synthesis 
To assess the relative importance of the de novo and 
salvage pathways in ATP synthesis, islets were cultured in 
the presence or absence of L-alanosine to block cytosolic 
l This figure may actually be a slight underestimate, since the action of 
IMPDH removes one tritium from the 2-position of [3H]hypoxanthine 
[12]. Thus, inhibition of IMPDH may itself lead to a slight increase in 
specific activity. 
2 We have observed the presence of nucleoside diphosphokinase in 
both cytosolic and membranous fractions of normal rat islets, human 
islets, and transformed /3cell lines [36]. 
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conversion of IMP to AMP via adenylosuccinate syn- 
thetase (Fig. 1; ref. [16]). Concentrations of 300-600 /.tM 
alanosine were determined to be equally and maximally 
effective to suppress ATP content: a 12% decrease in the 
mass of ATP was seen with 40 /xM L-alanosine, an 18% 
decrease with 100 /zM, and a 33% decrease with either 
300 or 600 /xM. Therefore the data using these latter 
concentrations were pooled for statistical analyses. 
In islets labeled with hypoxanthine, t-alanosine inhib- 
ited incorporation of label into ATP by 59% and total ATP 
content decreased by 30% (Table 1). Therefore, specific 
activity of the salvage pathway significantly dropped, by 
39%. In contrast, L-alanosine (as with the effect of MPA 
on GTP) had little effect on the labeling of ATP with 
[14C]glycine. Although mass again dropped significantly 
(by 26%), there was only a 17% decrease in incorporation 
of the [14C]glycine label (Table 1). Therefore, specific 
activity did not change (+ 6%). 
Our previous tudies howed that MPA also results in a 
decrease of islet ATP by approximately 40% [2,5], proba- 
bly secondary to the decrease in GTP, which is required as 
a phosphate donor in ATP synthesis (Fig. 1). In the present 
study, MPA again reduced total ATP content (by 44%) and 
decreased the incorporation of labeled hypoxanthine into 
ATP by 52% (Table 1). In islets labeled with glycine, the 
mass of ATP did drop as expected (by 30%), but the 
incorporation of [14C]glycine actually increased by 126%. 
These results are consistent with those involving GTP after 
MPA treatment and ATP after alanosine treatment. 
3.3. Additional evidence of low flux through the de novo 
pathway 
Glutamine is required in two of the first three steps in 
de novo purine nucleotide synthesis (ref. [4]; Fig. 1). In 
other cells, glutamine deficiency inhibits the de novo 
pathway [8]. To further assess the contribution of this 
pathway in pancreatic slets, glutamine was removed from 
the medium during the overnight culture period. This 
maneuver did not decrease GTP or ATP content by more 
than 9%, nor did it have any effect on insulin secretion 
(data not shown). Even with the simultaneous addition 
overnight of an inhibitor of endogenous glutamine synthe- 
sis (methionine sulfoximine; [17]), ATP and GTP contents 
were largely unaltered (0 to -4%). Furthermore, the 
glutamine antagonist azaserine [18] also failed to alter GTP 
or ATP content ( -  1% for both). Even the combination of 
azaserine and 6-methylmercaptopurine (6-MMPR; which 
inhibit the de novo pathway at different and sequential 
steps; [18,19]) only produced a small (16 to 21%, P < 0.05) 
decrease in GTP and ATP. In contrast, when islets were 
cultured in the presence of 300 /xM 6-mercaptopurine, 
which predominantly blocks salvage pathway activity by 
acting as a false substrate for hypoxanthine-guanine phos- 
phoribosyltransferase [20], islet GTP content fell by 74% 
and ATP decreased by 40% (Fig. 2 and Table 2). The large 
decrease in incorporation of [3H]hypoxanthine into ATP 
and GTP with 6-mercaptopurine (Fig. 2) is due to competi- 
tion of the label for coupling to PRPP. 
3.4. Insulin release in relationship to islet nucleotides 
We have previously reported that overnight culture of 
islets with MPA reduces ubsequent glucose-induced in- 
sulin secretion by 54% [2], an effect ascribable to the large 
decrease in GTP (but not the smaller decrement in ATP 
content). While the 'pool' of GTP which is functionally 
relevant was not identified in those studies, the specific 
activity data in the current study implicate cytosolic GTP 
derived via the salvage pathway. Overnight culture in 150 
or 300 /xM 6-mercaptopurine d creased incremental glu- 
cose-induced insulin secretion by 50% and 62% respec- 
tively (Table 2, and additional data not shown). Insulin 
content was also decreased by an average of 23%. How- 
ever, the decrease in subsequent glucose-induced insulin 
secretion remained significant even when expressed as 
fractional release (Table 2). 6-mercaptopurine had no sig- 
nificant effect on basal insulin secretion (i.e. 3.3 mM 
glucose), nor did it have any effect on insulin secretion 
when provided only during a 45 min pre-incubation period. 
Although its effects on glucose metabolism were not di- 
rectly assessed, 6-mercaptopurine (like MPA; ref. [2]) also 
significantly inhibited (by 22% to 25%) the insulin secre- 
tion induced by the non-hexose fuel a-ketoisocaproic a id 
(P < 0.001, 13 dr). 
In contrast o the effects on insulin secretion produced 
by manipulating cytosolic GTP, decrements in mitochon- 
drial GTP did not reduce insulin secretion (and actually 
promoted it; see Discussion). For example, an overnight 
exposure to 4.4 mM SAME (which was kept in the 
Table 2 
Effect of 6-mercaptopurine on nucleoside triphosphate l vels and insulin secretion 
Condition ATP (pmol/islet) GTP (pmol/islet) Incremental insulin release at 16.7 mM glucose Fractional release 
Control 16.07 + 0.26 (4) 3.73 + 0.08 (4) 443 + 23 (9) 5.26 _ 0.40 (9) 
6-mercaptopurine 300/xM 9.64 + 0.35 a (4) 0.96 + 0.03 a (4) 169 + 8 a (9) 2.80 + 0.34 a (9) 
Islets were cultured overnight in 11.1 mM glucose in the presence or absence of 300 /~M 6-mercaptopurine. Islets were extracted the next day for 
nucleotides. In the insulin studies, 6-mercaptopurine was also present in the 45 min pre-incubation period but was excluded from the 45 rain incubation 
period. 
Number in parentheses represents number of determinations (mean + S.E.). 
a p < 0.05 or greater vs. control (diluent alone). 
M. Meredith et al. / Biochimica et Biophysica Acta 1266 (1995) 16-22 21 
incubation medium) not only directly increased insulin 
secretion (from a basal level of 60_  8 /xU insulin/10 
islets at 3.3 mM glucose alone to 151 + 14/zU insulin/45 
min; P < 0.001, df 12), but also significantly potentiated 
the effects of 9.7 mM glucose or 5 mM KIC on insulin 
secretion (data not shown). 
In islets treated with 600 /zM L-alanosine, despite a 
33% decrease in ATP content, the insulin secretion subse- 
quently stimulated by 16.7 mM glucose was not signifi- 
cantly decreased (control = 391 _ 18; alanosine = 333 + 
29/zU insulin/45 min)./danosine decreased insulin con- 
tent by a 15% average, but still had no significant effect on 
insulin secretion when expressed as fractional release (con- 
trol = 4.42 ___ 0.47; alanosine = 4.67 ___ 0.31%/45 min). In 
addition, when 6-MMPR was provided at a higher concen- 
tration of 40 /zM (in order to inhibit the de novo pathway 
as well as to decrease PRPP; ref. [19]), a 40% decrease in 
ATP content was observed, but this again was not accom- 
panied by a significant effect on insulin secretion (data not 
shown). Thus, a decrease of total ATP by up to 40% (by 
alterations in the cytosolic synthesis of adenine nu- 
cleotides) appears to have had no significant effect on 
insulin secretion, at least when achieved subacutely. These 
findings support our previous observations using MPA to 
reduce islet ATP levels 
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The insulin secretion data support the conclusion that 
cytosolic GTP seems to be the functionally relevant pool. 
A decrease in total GTP content produced by the inhibitors 
MPA or 6-mercaptopurine resulted in a marked inhibition 
of subsequent glucose-induced insulin secretion. However, 
the decrease in (presumably) intramitochondrial GTP con- 
tent produced by the pure mitochondrial fuel SAME, actu- 
ally potentiated insulin release. Thus, cytosolic and mito- 
chondrial GTP may play different roles in insulin secre- 
tion. Whereas adequate cytosolic GTP appears to play a 
permissive role in secretion, other studies [13,35] support 
the possibility that mitochondrial GTP has, if anything, an 
inhibitory effect; it was postulated that a depletion of GTP 
(which is consumed in the conversion of succinic acid to 
succinyl CoA) could activate glutamate dehydrogenase and 
thereby increase insulin release 3. Our findings would 
support hese hypotheses. 
Blocking cytosolic synthesis of adenine nucleotides de- 
creases total ATP content by up to 42%. However, de- 
creasing total ATP content by this amount with MPA, 
alanosine or 6-MMPR had no effect on glucose-induced 
insulin secretion. This implies that the increase in ATP 
which is generally believed to play an early step in glu- 
cose-induced insulin secretion either is not acutely derived 
via cytosolic pathways, or else, that there are specific 
pools of ATP (perhaps that generated via the mito- 
chondria) that are more critical than total cellular ATP 
levels. Alternatively, reductions in ATP content might not 
impede insulin release if the ATP/ADP did not change; in 
fact, preliminary studies indicate that MPA reduced the 
GTP/GDP ratio but not the ATP/ADP ratio (Meredith, 
M. and Metz, S., in preparation). 
In summary, both the salvage and de novo purine 
nucleotide synthetic pathways are present in rat pancreatic 
islets; however, the salvage pathway appears to be most 
important. A marked depletion in total GTP content by 
alterations of the salvage pathway over 18 h impairs 
subsequent insulin secretion. In contrast, subacute de- 
creases in total ATP content do not appear to affect insulin 
secretion. 
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